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Abstract
Background—Recent data on digoxin prescribing and adverse events are lacking but could help 
inform the management of digoxin in contemporary heart failure treatment.
Methods and Results—We determined nationally-representative numbers and rates of 
emergency department (ED) visits for digoxin toxicity in the United States using 2005–2010 
reports from the National Electronic Injury Surveillance System—Cooperative Adverse Drug 
Event Surveillance project and the National Ambulatory (and Hospital Ambulatory) Medical Care 
Surveys. Based on 441 cases, an estimated 5,156 (95% confidence interval [CI], 2,663–7,648) ED 
visits for digoxin toxicity occurred annually in the United States; over three-fourths (78.8% [95% 
CI, 73.5%–84.1%]) resulted in hospitalization. Serum digoxin level was ≥2.0 ng/mL for 95.8% 
(95% CI, 93.2%–98.4%) of estimated ED visits with levels reported (n=251 cases). The rate of ED 
visits per 10,000 outpatient prescription visits among patients ≥85 years was twice that of patients 
40–84 years (rate ratio, 2.4 [95% CI, 1.2–5.0]); among females, the rate was twice that of males 
(rate ratio, 2.3 [95% CI, 1.1–4.7]). Digoxin toxicity accounted for an estimated 1.0% (95% CI, 
0.6%–1.4%) of ED visits for all adverse drug events (ADEs) among patients ≥40 years, but an 
estimated 3.3% (95% CI, 2.3%–4.4%) of ED visits and 5.9% (95% CI, 4.0%–7.9%) of 
hospitalizations for all ADEs among patients ≥85 years. Estimated annual ED visits and 
hospitalizations remained relatively constant from 2005–2010.
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Conclusion—Digoxin toxicity is not declining; more careful prescribing to high-risk groups and 
improved monitoring of serum levels might be needed to reduce morbidity from outpatient 
digoxin use.
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Introduction
Congestive heart failure causes over 900,000 admissions annually in the United States with 
a readmission rate exceeding 20% [1]. Many hospitals have implemented quality 
improvement initiatives to lower the burden of heart failure-related readmissions, and 
financial incentives from the Centers for Medicare and Medicaid Services for reducing such 
readmissions have recently been established [2, 3]. Despite interest in preventing heart 
failure admissions, novel therapies to reduce the frequency of heart failure complications 
have not been approved for use in United States in recent years. Neither large-scale clinical 
trials of novel pharmacological agents nor medical devices that detect increases in cardiac 
filling pressures have proven effective in decreasing heart failure hospitalizations [4, 5]. 
Digoxin, one of the oldest available treatments for heart failure, has declined in use over the 
past two decades in favor of agents with demonstrated mortality benefit but remains a 
common adjunctive therapy for heart failure, particularly in patients with refractory 
symptoms [6]. To further curb heart failure-related hospitalizations, some have recently 
suggested re-evaluating digoxin’s role in contemporary heart failure treatment [4, 7].
One of the important limitations to digoxin use remains its narrow therapeutic index as it 
contributes to development of cardiac and non-cardiac (e.g., central nervous system, 
gastrointestinal) toxicities [8]. Understanding the current epidemiology of digoxin toxicity 
could provide additional context for renewed considerations of digoxin use in heart failure. 
We used nationally representative public health surveillance data from the United States to 
estimate the frequency and rates of emergency department (ED) visits and hospitalizations 
for digoxin toxicity and to characterize the nature of these visits.
Methods
National estimates of the number of ED visits and subsequent hospitalizations for adverse 
drug events (ADEs) were based on data from the National Electronic Injury Surveillance 
System-Cooperative Adverse Drug Event Surveillance (NEISS-CADES) project, a national 
stratified probability sample comprised of 63 hospitals in the United States and its 
territories; this surveillance system, including its performance characteristics, has been 
previously described in detail [9–11]. For this analysis, only data from the 58 participating 
non-pediatric hospitals were used. In brief, trained abstractors at each hospital review 
clinical records of every ED visit to identify conditions that the treating clinician explicitly 
attributed to the use of a drug (i.e., prescription and over-the-counter medications, vaccines, 
and herbals/dietary supplements) or drug-specific adverse effects. Abstractors record up to 2 
medications implicated in each ADE by the treating clinician in addition to narrative 
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descriptions of the incidents, including physician diagnosis and clinical testing. Narrative 
descriptions are then coded using the Medical Dictionary for Regulatory Activities 
(MedDRA), an international terminology used to analyze ADE reports [12]. In this analysis, 
hospitalization was defined as admission to an inpatient unit of the healthcare facility, 
transfer to another healthcare facility, or billed as a hospital observation stay.
Patients younger than 40 years were involved in only 6.4% of all cases of digoxin-related 
adverse events reported to NEISS-CADES and were excluded from analysis. Cases of 
digoxin-related adverse events reported to NEISS-CADES from ED visits made between 
January 1, 2005 and December 31, 2010 were included if evidence of digoxin toxicity was 
present as indicated by documentation in the medical record narrative of any one of the 
following terms: “digoxin toxicity” or “drug toxicity,” documentation of administration of a 
digoxin dose greater than prescribed or intended (i.e., medication error), an elevated digoxin 
level (≥2.0 ng/mL), or at least one of the following signs/symptoms consistent with digoxin 
toxicity: cardiac dysrhythmias, gastrointestinal disturbances (anorexia, nausea, vomiting, or 
diarrhea), mental disturbances (anxiety, depression, delirium, hallucinations, weakness, 
apathy, confusion, or decreased level of consciousness), visual disturbances, or leg cramps. 
Clinical symptoms associated with digoxin toxicity were characterized based on MedDRA 
terms and grouped into hierarchical and mutually exclusive categories. To ensure that 
reported symptoms were related to digoxin and not another medication implicated in the ED 
visit, clinical symptoms were analyzed only for cases in which digoxin was the only 
offending medication (i.e., a second implicated medication was not recorded) and at least 
one clinical symptom was provided.
National estimates of the number of ambulatory care visits at which digoxin was prescribed 
were based on 2 national cross-sectional surveys of ambulatory medical care services: the 
National Ambulatory Medical Care Survey (NAMCS) and the National Hospital 
Ambulatory Medical Care Survey (NHAMCS), which involve a multistage sampling design 
of ambulatory care visits to non-federally employed office-based physicians and to EDs and 
outpatient departments of noninstitutional general and short-stay hospitals, exclusive of 
federal, military, and Veterans Administration hospitals [13]. For this analysis, we refer to 
all NAMCS/NHAMCS ambulatory care visits at which digoxin was prescribed or continued 
as “outpatient prescription visits.” We used public use data files for 2005–2010 to identify 
ambulatory care visits at which digoxin was prescribed or continued. Visits by patients 
younger than 40 years comprised 5.9% of all outpatient prescription visits for digoxin 
reported to NAMCS/NHAMCS and were excluded from analysis. Digoxin was identified by 
searching the 8 medication fields in each NAMCS/NHAMCS dataset for the Multum 
Lexicon Drug Database codes identifying relevant generic ingredients (i.e., digoxin, 
digitoxin, digitalis) [14–16].
Each selected NEISS-CADES, NAMCS, and NHAMCS record was accompanied by a 
sample weight based on inverse probability of selection, adjusted for nonresponse and post-
stratified to adjust for the number of annual hospital ED visits (NEISS-CADES), and 
adjusted for nonresponse and population changes incorporating weight smoothing (NAMCS/
NHAMCS) [9, 13, 17]. National estimates and percentages of ED visits and outpatient 
prescription visits, as well as corresponding 95% confidence intervals (CIs) were calculated 
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using the SURVEYMEANS procedure in SAS (version 9.3; SAS Institute Inc, Cary, North 
Carolina) to account for the sample weights and complex sample designs. The resulting 
frequency estimates and confidence limits derived from NEISS-CADES and NAMCS/
NHAMCS data were divided by 2 for the time periods 2005–2006, 2007–2008, and 2009–
2010 to obtain annual estimates representing these three periods; and were divided by 6 for 
the time period 2005–2010 to obtain annual estimates representing the entire study period. 
Estimates based on small numbers of cases (<20 cases for NEISS-CADES and <30 cases for 
NAMCS/NHAMCS) or with a coefficient of variation greater than 30% were considered 
statistically unstable and are not presented here.
To estimate rates of ED visits for digoxin toxicity relative to outpatient medication use, we 
divided the estimated number of ED visits for digoxin toxicity by the estimated number of 
outpatient prescription visits for digoxin. Calculation of the 95% CI for each rate 
incorporated variance estimates for both numerator and denominator components of the 
corresponding rate estimate [18]. Because these components were calculated from separate 
surveillance systems, they were treated as independent (and, thus, as having zero 
covariance).
Rate ratios (RRs) were used to compare rates of ED visits for digoxin toxicity relative to 
outpatient medication use between different patient populations. Estimated 95% CIs for the 
RRs were calculated using an initial logarithmic transformation and incorporated the 
estimated variances of the numerators and denominators of both component rate estimates 
[18, 19]. The component rate estimates were again assumed to be independent across patient 
populations.
Data collection, management, quality assurance, and analyses were determined to be public 
health surveillance activities by the Centers for Disease Control and Prevention (CDC) and 
U.S. Food and Drug Administration human subjects oversight bodies and, therefore, did not 
require human subjects review or institutional review board approval.
Results
Between 2005 and 2010, 443 cases of digoxin-related adverse events among patients 40 
years or older were reported to NEISS-CADES. Two cases were digoxin-related allergic 
reactions. The remaining 441 met criteria for inclusion in the analysis. Based on these 441 
cases, an estimated 5,156 ED visits (95% CI, 2,663–7,648) for digoxin toxicity among 
patients 40 years or older occurred annually in the United States during 2005–2010 (Table 
1). The estimated number of ED visits for digoxin toxicity remained relatively constant over 
time. The majority of ED visits for digoxin toxicity occurred among females (67.8% [95% 
CI, 62.9%–72.6%]), patients 70 years or older (79.1% [95% CI, 73.5%–84.7%]), and 
patients of white race (70.3% [95% CI, 56.7%–83.8%]). During 2005–2010, digoxin toxicity 
accounted for an estimated 1.0% (95% CI, 0.6%–1.4%) of ED visits for all ADEs among 
patients 40 years or older: an estimated 0.7% (95% CI, 0.4%–1.1%) of ED visits for all 
ADEs among patients 40–84 years, and an estimated 3.3% (95% CI, 2.3%–4.4%) of ED 
visits for all ADEs among patients 85 years or older.
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Overall, over three-fourths (78.8% [95% CI, 73.5%–84.1%]) of estimated ED visits for 
digoxin toxicity resulted in hospitalization; this was also true across all age groups (Table 1). 
In contrast, for medications other than digoxin, the estimated proportion of ED visits for 
ADEs resulting in hospitalization was 20.6% (95% CI, 16.8%–24.3%) in patients 40–69 
years, 36.5% (95% CI, 30.6%–42.4%) in patients 70–84 years, and 43.2% (95% CI, 36.8%–
49.7%) in patients 85 years or older. Among patients 85 years or older, digoxin toxicity was 
the cause of an estimated 5.9% (95% CI, 4.0%–7.9%) of hospitalizations related to all 
ADEs. The proportion of ED visits for digoxin toxicity resulting in hospitalization remained 
relatively constant over time (Table 1).
Among cases where the serum digoxin level was recorded (251 cases), a level ≥2.0 ng/mL 
was present in an estimated 95.8% (95% CI, 93.2%–98.4%) of ED visits for digoxin toxicity 
(Table 2). In 369 of the 441 reported cases, digoxin was considered the only offending drug 
related to the ED visit. Clinical symptoms were recorded for 365 of these cases (Table 3). In 
over two-thirds of estimated ED visits, symptoms affecting the central nervous system 
(25.2% [95% CI, 17.4%–33.1%]) or cardiovascular system (44.5% [95% CI, 37.3%–
51.7%]) were recorded. Cases in which only gastrointestinal symptoms were recorded 
comprised a minority of ED visits for digoxin toxicity (9.7% [95% CI, 5.8%–15.5%]). All 
other types of symptoms (e.g., fatigue, myalgias) were documented in an estimated 11.9% 
(95% CI, 8.0%–15.8%) of ED visits. Medication errors (i.e., administration of a digoxin 
dose higher than prescribed or intended) were documented in too few cases (11 of 369 
[3.0%] cases where digoxin was the only offending drug documented) to be able to report a 
national estimate.
Accounting for the number of outpatient prescription visits for digoxin, estimated rates of 
ED visits for digoxin toxicity were essentially constant throughout the study period (Table 
4). However, the rates of ED visits for digoxin toxicity increased with age: the rate of ED 
visits per 10,000 outpatient prescription visits among patients 85 years or older was twice 
that of patients younger than 85 years (10.8 [95% CI, 6.1–15.6] vs. 4.5 [95% CI, 1.9–7.0] 
ED visits per 10,000 outpatient prescription visits; RR, 2.4 [95% CI, 1.2–5.0]); in particular 
the rate was 3 times that of patients 40–69 years (RR, 3.0 [95% CI, 1.4–6.2]). Females had 
twice the rate of ED visits for digoxin toxicity when compared with males (7.8 [95% CI, 
4.2–11.5] vs. 3.5 [95% CI, 1.5–5.4] ED visits per 10,000 outpatient prescription visits; RR, 
2.3 [95% CI, 1.1–4.7]).
Discussion
In 1997, over 20 million prescriptions for digoxin were written in the United States, placing 
it among the 20 most commonly prescribed medications [20]. In ensuing years, after the 
Digoxin Investigation Group (DIG) trial found that digoxin use reduced the rate of 
hospitalizations in heart failure patients but had no effect on mortality, digoxin lost favor as 
a first-line agent in the treatment of heart failure since other medications with a 
demonstrated mortality benefit had emerged [21–23]. The annual number of prescriptions 
for digoxin and admissions for digoxin toxicity subsequently declined through 2004 [24, 
25]. Our analysis indicates that ED visits for digoxin toxicity did not decrease further during 
2005–2010, with over 5,000 estimated ED visits occurring annually.
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These events involved considerable morbidity. Over three-quarters of estimated ED visits 
for digoxin toxicity resulted in hospitalizations. In addition, we estimated that over one-
fourth of ED visits for digoxin toxicity involved symptoms affecting the central nervous 
system and that arrhythmias and syncopal episodes comprised many of the cardiovascular 
manifestations, the principal presentation for almost half of ED visits. Our analysis might 
actually underestimate the proportion of ED visits involving these severe presenting 
symptoms, since in 47 cases only the treating clinician’s diagnosis of “digoxin toxicity” was 
recorded (without the patient’s exact presenting symptoms).
Accounting for outpatient prescription frequency, we found females and older adults to have 
disproportionately high rates of ED visits for digoxin toxicity. It remains debated whether 
females are biologically more susceptible to development of digoxin toxicity [26, 27]; 
however, our data suggest that, in practice, females are affected by digoxin toxicity at higher 
rates. Digoxin toxicity was also an important reason for ED visits for ADEs among older 
adults, accounting for over 1 of 20 of such visits in adults 85 years or older. In contrast to 
other medications commonly implicated in emergent hospitalizations for ADEs in older 
adults, which lead to hospitalization in an estimated 20%–50% of visits [28], we found the 
estimated rate of hospitalization for digoxin toxicity to be 75%. Older adults are at greater 
risk for adverse effects from all medications because of altered pharmacokinetics or 
polypharmacy [29]. Older adults with heart failure might furthermore be at particular risk 
for developing digoxin toxicity due to concomitant comorbidities such as hypokalemia 
(from diuretic use) or renal impairment [29, 30].
Potential benefits of prescribing digoxin for heart failure patients have been reported based 
on secondary analyses of DIG trial data [31–34]. New clinical trials would be needed to 
confirm the efficacy of digoxin as an adjunct to contemporary medical therapy for heart 
failure. This study does not examine the risk/benefit ratio of increased use of digoxin, but we 
have used public health surveillance data to focus on the risk of digoxin toxicity and provide 
insight into potential ways to minimize the harms resulting from digoxin use. By identifying 
patient subpopulations at increased risk of digoxin toxicity, our findings point to the 
following considerations if digoxin is to be increasingly used as an adjunctive measure to 
prevent heart failure admissions.
First, careful patient selection for digoxin therapy, proper initial dosing, and heightened 
surveillance for high-risk patients, such as females and older adults, might mitigate the 
burden of ED visits and hospitalizations for digoxin toxicity. Second, consistent guidance 
for what constitutes a therapeutic serum digoxin level might also reduce the incidence of 
patients presenting with toxicity. The levels reported for most ED visits for digoxin toxicity 
were ≥2.0 ng/mL. Clinical practice guidelines suggest that serum digoxin levels 0.5–0.9 
ng/mL are therapeutic for heart failure and that higher levels might be harmful [35]. 
However, dissemination of 0.5–0.9 ng/mL as the standard reference range is inconsistent; 
many sources still indicate 2.0 ng/mL as the upper level of the therapeutic range for serum 
digoxin levels [8]. Furthermore, many hospital laboratories still consider digoxin levels of 
2.0 ng/mL to be within normal range [36]. Targeting the lower range would likely further 
reduce the number of patients who inadvertently experience digoxin toxicity from serum 
digoxin levels that are clearly supratherapeutic. Third, incorporating prevention of digoxin 
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toxicity into current strategies for reducing heart failure readmissions represents a potential 
means of intervention for the at-risk population. This is corroborated by data indicating 
increased risk of hospitalization for digoxin toxicity following hospitalization [37]. Existing 
programs for reducing heart failure readmissions focus on medication reconciliation, patient 
compliance with medications, electronic medical orders, and careful and close follow-up 
during transitions of care from the inpatient to outpatient setting [38]. To prevent digoxin 
toxicity, merely ensuring that patients are taking the medication as prescribed is likely to 
have limited utility, particularly considering that few of our reported cases were due to 
medication errors. However, given their potential ability to manage patients whose care is 
coordinated by multiple providers, readmission reduction programs may provide a 
framework that can be leveraged to improve monitoring and follow-up of digoxin levels.
This study’s findings should be interpreted in the context of the limitations of public health 
surveillance data. First, NEISS-CADES only captures ADEs resulting in ED visits or 
emergent hospitalizations. Thus, clinical episodes of digoxin toxicity resulting in lower 
levels of care (e.g., physician office visits) or direct admissions to the hospital would not 
have been identified. Additionally, digoxin toxicity might go unrecognized during an ED 
visit and would not be reported if it were diagnosed during hospitalization after the ED visit. 
NEISS-CADES also does not include data on length of stay for patients hospitalized for 
digoxin toxicity. Second, NAMCS/NHAMCS imperfectly measure outpatient prescribing 
frequency as they exclude prescriptions initiated by phone and e-mail contacts as well as 
prescriptions initiated in nursing homes, in ambulatory surgery centers, or provided at 
hospital discharge. However, we would not expect this to affect the relative magnitude of 
the risks of digoxin toxicity between genders. Although NAMCS/NHAMCS data may be 
underestimates of outpatient prescription visits for older adults, previous studies have also 
found older adults to be at higher risk of digoxin toxicity compared to younger patients [39, 
40]. Third, we did not have sufficient information from all cases to ascertain the indication 
for digoxin use; thus these data might include patients being treated for indications other 
than heart failure (e.g., atrial fibrillation). Fourth, we did not have information in all cases 
about such variables as electrolyte levels, renal function, and concomitant medications and 
thus could not fully characterize factors leading to digoxin toxicity. This is important in that 
digoxin might be currently considered more often for patients with advanced heart failure, 
who have the greatest risk for renal impairment and thus digoxin toxicity. Fifth, we do not 
have a record of the indication for hospitalization in our cases. As patients with heart failure 
have high rates of hospitalization in general, some of the hospitalizations described could 
have been for patients’ underlying illnesses rather than digoxin use per se. However, given 
that the incident emergency department visits were related to use of digoxin, it is likely that 
most of the subsequent hospitalizations were related to digoxin use as well.
Digoxin continues to have a niche in the treatment of patients with symptomatic heart failure 
who are refractory to other treatments [41]. National public health surveillance data indicate 
that digoxin use and the burden of digoxin toxicity as measured by ED visits and 
hospitalizations did not decline from 2005 through 2010. The lack of decline in digoxin 
toxicity over this time period could be due to a number reasons, including unchanged 
frequency of digoxin prescribing during this time, continued used of high reference ranges 
(e.g., an upper limit of 2.0 ng/mL) for serum digoxin levels, or lack of effective strategies 
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targeted at safely managing digoxin therapy among patients at highest risk of adverse 
events. Efforts to minimize morbidity from toxicity when digoxin use is considered might 
require prevention strategies focused on identifying the patient populations most likely to 
benefit from digoxin therapy, careful prescribing to high-risk populations (i.e., females and 
older adults) and improving monitoring and management of digoxin levels, including 
promoting adherence to lower ranges (e.g., 0.5–0.9 ng/mL) for serum digoxin levels.
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Table 2
Number of Cases and National Estimates of Emergency Department Visits for Digoxin Toxicity Among 
Persons Age 40 Years or Older, by Serum Digoxin Levels Reported—United States, 2005–2010
Serum Digoxin Level Reported (n=251 cases)*
Emergency Department Visits
Annual National Estimate
Cases, No. % 95% Confidence Interval
Level (ng/mL)
0.0–0.9 3 - -
1.0–1.9 8 - -
2.0–2.9 121 54.2 43.8–64.5
3.0–3.9 87 28.5 19.7–37.4
≥4.0 32 12.5 6.9–18.1
Case counts and estimates from the National Electronic Injury Surveillance System - Cooperative Adverse Drug Event Surveillance project, 2005–
2010, Centers for Disease Control and Prevention. Estimates with case count <20 or coefficient of variation >30% are considered unstable and are 
not shown (-).
*
Data are shown only for cases where a serum digoxin level was documented (251 of 441 cases).
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Table 3
Number of Cases and National Estimates of Emergency Department Visits for Digoxin Toxicity Among 




Cases, No. % 95% Confidence Interval
Category†
 Central nervous system 84 25.2 17.4–33.1
  Altered mental status 63 17.2 11.1–23.4
  Other central nervous system manifestation 21 8.1 4.7–11.5
 Cardiovascular 152 44.5 37.3–51.7
  Symptomatic disturbance in rate/rhythm‡ 41 10.6 6.4–14.9
  Syncope 44 12.5 7.4–17.5
  Dyspnea 35 11.9 6.5–17.2
  Other cardiovascular system manifestation 32 9.5 6.3–12.8
 Gastrointestinal 43 9.7 5.8–13.5
 Other symptoms 39 11.9 8.0–15.8
 Only “elevated digoxin level” or “digoxin toxicity” recorded§ 47 - -
Case counts and estimates from the National Electronic Injury Surveillance System - Cooperative Adverse Drug Event Surveillance project, 2005–
2010, Centers for Disease Control and Prevention. Estimates with case count <20 or coefficient of variation >30% are considered unstable and are 
not shown (−).
*
Data are shown only for cases where digoxin was the only offending drug implicated in the ED visit and at least one clinical symptom was 
provided (365 of 441 cases).
†
Categories are mutually exclusive and were assigned hierarchically. For example, a case where a patient presented with both confusion and 
bradycardia would be categorized under the category “Central nervous system.”
‡
Includes symptomatic bradycardia/bradyarrhythmias (29 cases), palpitations without rate/rhythm specified (6 cases), tachycardia/tachyarrhythmia 
(4 cases), and rate disturbance not otherwise specified (2 cases)
§
Presenting clinical symptoms not recorded for these cases.
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Table 4
Rates of Emergency Department Visits for Digoxin Toxicity Among Persons Age 40 Years or Older Per 
Outpatient Prescription Visits, by Patient Age and Sex, and Year of Visit—United States, 2005–2010
Annual National Estimate, No. ED Visits per 10,000 OPVs
ED Visits OPVs Rate 95% Confidence Interval
Age (yrs)
40–69 1,076 2,969,993 3.6 1.5–5.8
70–84 2,339 4,685,053 5.0 2.0–8.0
≥85 1,741 1,605,531 10.8 6.1–15.6
Sex
Male 1,662 4,803,080 3.5 1.5–5.4
Female 3,493 4,457,497 7.8 4.2–11.5
Year of ED Visit
2005–2006 5,163 9,441,084 5.5 2.1–8.8
2007–2008 5,275 9,183,850 5.7 2.6–8.9
2009–2010 5,031 9,156,796 5.5 2.4–8.6
ED indicates emergency department; OPV, Outpatient Prescription Visits.
ED visit estimates from the National Electronic Injury Surveillance System - Cooperative Adverse Drug Event Surveillance project, 2005–2010, 
Centers for Disease Control and Prevention. OPV estimates from the National Ambulatory Medical Care Survey and the National Hospital 
Ambulatory Medical Care Survey, 2005–2010, Centers for Disease Control and Prevention.
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